Literature DB >> 11960326

The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia.

J T Lee1, J A McCubrey.   

Abstract

The Raf/MEK/ERK (MAPK) signal transduction cascade is a vital mediator of a number of cellular fates including growth, proliferation and survival, among others. The focus of this review centers on the MAPK signal transduction pathway, its mechanisms of activation, downstream mediators of signaling, and the transcription factors that ultimately alter gene expression. Furthermore, negative regulators of this cascade, including phosphatases, are discussed with an emphasis placed upon chemotherapeutic intervention at various points along the pathway. In addition, mounting evidence suggests that the PI3K/Akt pathway may play a role in the effects elicited via MAPK signaling; as such, potential interactions and their possible cellular ramifications are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960326     DOI: 10.1038/sj.leu.2402460

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  45 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

Review 3.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

4.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

5.  Protein phosphatase 1γ isoforms linked interactions in the brain.

Authors:  Sara L C Esteves; Luís Korrodi-Gregório; Cândida Z Cotrim; Paula J M van Kleeff; Sara C Domingues; Odete A B da Cruz e Silva; Margarida Fardilha; Edgar F da Cruz e Silva
Journal:  J Mol Neurosci       Date:  2012-10-19       Impact factor: 3.444

Review 6.  MicroRNA and signaling pathways in gastric cancer.

Authors:  Z Zhang; Z Li; Y Li; A Zang
Journal:  Cancer Gene Ther       Date:  2014-07-25       Impact factor: 5.987

7.  In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

Authors:  Girija Dasmahapatra; Hiral Patel; Johnathan Friedberg; Steven N Quayle; Simon S Jones; Steven Grant
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

8.  Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.

Authors:  Morgan O'Hayre; Catherina L Salanga; Thomas J Kipps; Davorka Messmer; Pieter C Dorrestein; Tracy M Handel
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

9.  EhMAPK, the mitogen-activated protein kinase from Entamoeba histolytica is associated with cell survival.

Authors:  Anupama Sardar Ghosh; Doel Ray; Suman Dutta; Sanghamitra Raha
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

10.  MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.

Authors:  A A Rambal; Z L G Panaguiton; L Kramer; S Grant; H Harada
Journal:  Leukemia       Date:  2009-04-30       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.